Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

INAB - IN8BIO, INC.

IEX Last Trade
0.2521
0.006   2.499%

Share volume: 11,063
Last Updated: Thu 26 Dec 2024 08:16:34 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$0.25
0.01
2.56%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-2.25%
1 Month
-24.32%
3 Months
-17.68%
6 Months
-73.34%
1 Year
-83.59%
2 Year
-86.75%
Key data
Stock price
$0.25
P/E Ratio 
0.00
DAY RANGE
$0.24 - $0.25
EPS 
$0.00
52 WEEK RANGE
$0.23 - $1.93
52 WEEK CHANGE
-$83.48
MARKET CAP 
24.629 M
YIELD 
N/A
SHARES OUTSTANDING 
46.787 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.60
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$617,249
AVERAGE 30 VOLUME 
$785,538
Company detail
CEO: William T. Ho
Region: US
Website: in8bio.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, which is in Phase I clinical trial for glioblastoma and solid tumors. InB-100, an allogeneic product candidate, is in clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation.

Recent news